drugset / Trial / NCT05532527

Efficacy and Safety of Microwave Ablation Combined With Camrelizumab and Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer: a Multicenter, Open, Prospective Study

NCT05532527

NaSingle-groupOpen-labelTreatment

Summary

To evaluate the efficacy and safety of microwave ablation combined with Camrelizumab and chemotherapy in the treatment of patients with advanced non-small cell lung cancer.

Timeline

Start
2022-09-20
Primary completion
2023-09-20
Completion
2025-09-20

Drugs

EvaluationDrugModalityDoseRoute
Background Camrelizumab Monoclonal antibody